Gevokizumab is a monoclonal antibody that shuts down inflammation brought on by a protein in our bodies called interleukin-1 beta.
The pharma that produces Gevokizumab has been focusing on diabetes but now, with the orphan drug status , it means that it will get financial help to trial the drug on non-infectious and pan uveitis.
We don’t know, at this stage, whether is will work on Birdshot, but it is exciting to see new drugs coming on to the market. It is even more exciting to see pharmas getting orphan drug status for new medications.
Read the full article at: